Female infertility
Drug research and approvals for female infertility: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 130 studies of female infertility are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 130
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- Effect of Sirolimus on Oocyte Quality in Women Undergoing IVFNCT07936227 · Phase 4 · Center for Human Reproduction · starts Feb 25, 2026
- Dual Trigger VS HCG Trigger for Final Oocyte Maturation in Normal RespondersNCT07861399 · Not applicable · Al-Azhar University · starts Sep 1, 2026
- Machine-Learning Prediction of Pregnancy Outcomes After Assisted Reproductive TreatmentsNCT07855783 · Not reported · BetaPlus Center for Reproductive Medicine · starts Jan 1, 2026
- Artificial Intelligence Into Ultrasound Diagnostics in Reproductive MedicineNCT07810920 · Not reported · Semmelweis University · starts Sep 1, 2026
- Hormone-free Antral Retrieval for Viable Embryo Storage & TransferNCT07801105 · Not applicable · Kevin Doody · starts Sep 1, 2026
- The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF ProcessNCT07783399 · Not applicable · The Obstetrics and Gynaecology Clinic Narodni Front · starts May 15, 2026
- 225 IU Versus 300 IU Starting FSH Dose in PPOS for Good-Prognosis WomenNCT07772375 · Not applicable · Vietnam Military Medical University · starts Sep 15, 2026
- Guangdong Provincial Endometriosis Clinical Research CohortNCT07749053 · Not reported · Li Li · starts Feb 2, 2026
- Mobile Health Support Before Oocyte Pick-Up in Infertile WomenNCT07690969 · Not applicable · Istinye University · starts Oct 12, 2026
Approved 4
- Lutropin alfaLuteinizing hormone/Choriogonadotropin receptor agonist
- Follitropin alfaFollicle stimulating hormone receptor agonist
- Choriogonadotropin alfaLuteinizing hormone/Choriogonadotropin receptor agonist
- GanirelixGonadotropin-releasing hormone receptor antagonist
Phase 3 3
- ProgesteroneProgesterone receptor agonist
- DydrogesteroneProgesterone receptor agonist
- AcetylcysteineGlutathione precursor
Phase 2 1
- ClomipheneEstrogen receptor alpha modulator
Phase 1 or earlier 6
- SomatropinGrowth hormone receptor agonist
- FollitropinFollicle stimulating hormone receptor agonist
- MenotropinsLuteinizing hormone/Choriogonadotropin receptor agonist
- SildenafilPhosphodiesterase 5A inhibitor
- UrofollitropinFollicle stimulating hormone receptor agonist
- Ethinyl estradiolEstrogen receptor alpha agonist
How its trials ended
496 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 54 whose ending is known, 35% met their primary endpoint, 13% missed it and 52% stopped early.
- Completed, result not reported19339%
- Status unknown12625%
- Ongoing12325%
- Met its primary endpoint194%
- Stopped: other or unclear184%
- Stopped: enrollment or feasibility82%
- Missed its primary endpoint71%
- Stopped: lack of efficacy1<1%
- Stopped: sponsor or business decision1<1%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| May 2, 1996 | PuregonFollitropin beta | Organon N.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA